In the OASIS-1 study, 13% of participants (people with obesity without diabetes) receiving oral semaglutide 50 mg experienced altered skin sensation events compared to 1% with placebo - these events were generally mild to moderate in severity, occurred during dose escalation to the higher doses and resolved without requiring permanent treatment discontinuation [21]
While the mechanisms responsible for these potent effects remain incompletely understood, contributors include altered postprandial nutrient delivery to the intestine, increased secretion of glucagon-like peptide 1 (GLP-1) by intestinal L cells, increased insulin secretion, intestinal mucosal adaptations, alterations in the gut-brain axis, and changes in bile acid content and composition (3, 4)
"GLP-1 receptor agonists vs
How the Combination Works in the Body: Semaglutide B12 compounds combine the weight loss properties of semaglutide with the essential nutrient vitamin B12
Scientific and effective treatment options for weight loss are urgently needed in China Overweight and obesity are chronic metabolic diseases characterized by excessive fat accumulation in the body
